X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs VENUS REMEDIES - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES VENUS REMEDIES DIVIS LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x 30.0 -693.1 - View Chart
P/BV x 5.2 0.2 2,565.4% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 DIVIS LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
VENUS REMEDIES
Mar-16
DIVIS LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,222218 560.6%   
Low Rs78482 954.9%   
Sales per share (Unadj.) Rs153.1365.6 41.9%  
Earnings per share (Unadj.) Rs39.91.5 2,688.1%  
Cash flow per share (Unadj.) Rs44.637.9 117.6%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.8382.5 52.8%  
Shares outstanding (eoy) m265.4711.44 2,320.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.60.4 1,596.3%   
Avg P/E ratio x25.1101.0 24.9%  
P/CF ratio (eoy) x22.54.0 568.4%  
Price / Book Value ratio x5.00.4 1,267.1%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2661,717 15,511.5%   
No. of employees `0009.71.0 954.4%   
Total wages/salary Rs m4,687324 1,444.9%   
Avg. sales/employee Rs Th4,175.04,100.7 101.8%   
Avg. wages/employee Rs Th481.5318.0 151.4%   
Avg. net profit/employee Rs Th1,089.316.7 6,535.7%   
INCOME DATA
Net Sales Rs m40,6434,183 971.7%  
Other income Rs m74920 3,725.9%   
Total revenues Rs m41,3924,203 984.9%   
Gross profit Rs m14,460812 1,781.7%  
Depreciation Rs m1,233417 295.9%   
Interest Rs m23380 6.0%   
Profit before tax Rs m13,95335 39,753.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,34918 18,503.8%   
Profit after tax Rs m10,60417 62,377.7%  
Gross profit margin %35.619.4 183.4%  
Effective tax rate %24.051.6 46.5%   
Net profit margin %26.10.4 6,419.4%  
BALANCE SHEET DATA
Current assets Rs m40,1052,771 1,447.5%   
Current liabilities Rs m6,5951,931 341.4%   
Net working cap to sales %82.520.1 410.9%  
Current ratio x6.11.4 423.9%  
Inventory Days Days119125 94.8%  
Debtors Days Days8154 150.1%  
Net fixed assets Rs m19,9955,328 375.2%   
Share capital Rs m531114 464.1%   
"Free" reserves Rs m53,0434,177 1,269.9%   
Net worth Rs m53,5744,376 1,224.2%   
Long term debt Rs m01,911 0.0%   
Total assets Rs m61,5858,428 730.7%  
Interest coverage x618.41.1 56,609.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.70.5 133.0%   
Return on assets %17.34.7 366.5%  
Return on equity %19.80.4 5,095.4%  
Return on capital %26.16.6 395.3%  
Exports to sales %00-   
Imports to sales %25.220.5 123.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259858 1,195.3%   
Fx inflow Rs m35,3840-   
Fx outflow Rs m10,399858 1,211.5%   
Net fx Rs m24,985-858 -2,911.0%   
CASH FLOW
From Operations Rs m11,493469 2,451.6%  
From Investments Rs m-11,37229 -38,943.8%  
From Financial Activity Rs m-93-464 20.1%  
Net Cashflow Rs m2835 82.3%  

Share Holding

Indian Promoters % 52.0 32.9 158.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.2 6,555.6%  
FIIs % 19.0 0.6 3,275.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 66.4 25.9%  
Shareholders   31,796 20,121 158.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS